Small-molecule Bcl-2 antagonists as targeted therapy in oncology
2008
Small-molecule Bcl-2 antagonists as targeted therapy in oncology
publication
Evidence: moderate
Author Information
Author(s): Warr M.R., Shore G.C.
Primary Institution: McGill University
Hypothesis
Targeting pro-survival Bcl-2 family members can alleviate the block to apoptosis in cancer cells.
Conclusion
Small-molecule Bcl-2 antagonists show promise in selectively killing malignant cells by overcoming resistance to apoptosis.
Supporting Evidence
- Obatoclax has shown single-agent activity against various cancer cell lines.
- ABT-737 demonstrated cytotoxicity in select tumor models.
- (–)-Gossypol has been effective in various cancer cell lines and shows synergy with other treatments.
Takeaway
Scientists are studying special drugs that can help kill cancer cells by making them go through a process called apoptosis, which is like a cell's way of saying goodbye when it's damaged.
Methodology
The study reviews the progress of small-molecule Bcl-2 antagonists in clinical trials and their mechanisms of action.
Limitations
The review does not provide specific clinical trial data or detailed statistical analyses.
Want to read the original?
Access the complete publication on the publisher's website